Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
Regenerative medicine company, Regeneus Ltd (ASX:RGS) is pleased to announce the appointment of Dr Glen Richards as an independent non-executive director of Regeneus with effect from April.
Regenerative medicine company, Regeneus Ltd (ASX:RGS), today reported its financial results for the half-year ended 31 December 2014.
Regeneus Ltd (ASX:RGS) Regeneus Half-Yearly Appendix 4D and Accounts. Following is the review of operations for the period.
Regenerative medicine company, Regeneus Ltd (ASX:RGS), announced today the granting by the Australian Patent Office of Australian patent number 2013203072. This Regeneus owned patent covers a method for freezing cells that maintains viability and functionality of the cells.
Regeneus Ltd (ASX:RGS) announces that the new Japanese regenerative medicine laws that passed through Parliament in November 2013, have come into effect. These new laws reform the pharmaceutical and medical regulations related to regenerative medicine and provide a rapid approval process specifically designed for regenerative medicine products.
Regenerative medicine company, Regeneus Ltd (ASX:RGS), announces that it has completed a strategic review of the business resulting in the company taking a number of measures to streamline its management structure, operations and reduce costs.
Regenerative medicine company, Regeneus Ltd (ASX:RGS), announces today the granting by the Australian Patent Office of Australian patent number 2013203164. This Regeneus owned patent, Therapeutics for skin conditions, provides protection for the company's stem cell secretions technology for the topical treatment of acne.
Regenerative medicine company, Regeneus Ltd (ASX:RGS), announces changes to its Board and senior management team consistent with its focus on increasing commercial and partnering activities for its regenerative medicine products, reducing costs and greater Board independence.
Regeneus Ltd (ASX:RGS) Presentation to Shareholders at AGM 2014 with significant achievements to date including the successful translation of 4 regenerative medicine technology platforms into products for musculoskeletal and oncology applications for humans and animals.
Together with the company's committed and capable management and staff, the Board is intent on realising Regeneus' full potential, not only to deliver significant benefits to both human and animal health but also to justify shareholders' faith in Regeneus through enhancing the value of your investment in the company.
Appendix 4G and Corporate Governance Statement
Appendix 3Z - Final Director's Interest Notice
Appendix 4D and Half-Year Report
